Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague

Vaccine

Volumn 21, Issue 21-22, 2003, Pages 3051-3057

  Garmory, Helen S ^a   Griffin, Kate F ^a   Brown, Katherine A ^b   Titball, Richard W ^a,c  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Plague; Salmonella enterica serovar Typhimurium; V antigen

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; LIVE VACCINE; PLAGUE VACCINE; PLASMID VECTOR; UNCLASSIFIED DRUG; YERSINIA PESTIS V ANTIGEN;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DELIVERY SYSTEM; FEMALE; GENETIC CODE; IMMUNE RESPONSE; IMMUNOBLOTTING; IN VITRO STUDY; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; PROTECTION; SALMONELLA ENTERICA; SEROTYPE; YERSINIA PESTIS;

EID: 0037836113     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00112-9     Document Type: Article

References (33)

1. Perry R.D., Fetherstone J.D. Yersinia pestis - etiologic agent of plague. Clin. Microbiol. Rev. 10:1997;35-66.
2. World Health Organisation. Human Plague in 1994. Wkly Epidemiol Rec 1994;71:165-72.
3. Cavanaugh D.C., Elisberg B.L., Llewellyn C.H.et al. Plague immunization. V. Indirect evidence for the efficacy of plague vaccine. J. Infect. Dis. 129:1974;S37-40.
4. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., Titball R.W. A sub-unit vaccine elicits IgG in serum. Vaccine. 15:1997;1079-1084.
5. Cohen R.J., Stockard J.L. Pneumonic plague in an untreated plague-vaccinated individual. JAMA. 202:1967;356-357.
6. Marshall J.D. Jr., Bartelloni P.J., Cavanaugh D.C., Kadull P.J., Meyer K.F. Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J. Infect. Dis. 129:1974;S19-25.
7. Leary S.E.C., Williamson E.D., Griffin K.F., Russell P., Eley S.M., Titball R.W. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect. Immun. 63:1995;2854-2858.
8. Anderson G.W. Jr., Leary S.E., Williamson E.D.et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Y. pestis. Infect. Immun. 64:1996;4580-4585.
9. Williamson E.D., Eley S.M., Griffin K.F.et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol. Med. Microbiol. 12:1995;223-230.
10. Heath D.G., Anderson G.W. Jr., Mauro J.M.et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine. 16:1998;1131-1137.
11. 2+ response virulence genes. J. Bacteriol. 173:1991;2649-2657.
12. Pettersson J., Holmström A., Hill J.et al. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol. Microbiol. 32:1999;961-976.
13. Fields K.A., Nilles M.L., Cowan C., Straley S.C. Virulence role of V antigen of Yersinia pestis at the bacterial cell surface. Infect. Immun. 67:1999;5395-5408.
14. Nakajima R., Brubaker R.R. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumour necrosis factor alpha. Infect. Immun. 61:1993;23-31.
15. Nakajima R., Motin V.L., Brubaker R.R. Supression of cytokines in mice by protein A-V antigen peptide and restoration of synthesis by active immunisation. Infect. Immun. 63:1995;3021-3029.
16. Nedialkov Y.A., Motin V.L., Brubaker R.R. Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistadine fusion peptide: amplification of interleukin-10. Infect. Immun. 65:1997;1196-1203.
17. Welkos S., Friedlander A., McDowell D., Weeks J., Tobery S. V antigen of Yersinia pestis inhibits neutraphil chemotaxis. Microb. Pathog. 24:1998;185-196.
18. Cardenas L., Clements J.D. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin. Microbiol. Rev. 5:1992;328-342.
19. Chatfield SN, Dougan G, Roberts M. Progress in the development of multivalent oral vaccines based on live attenuated Salmonella. In: Kurstak E, editor. Modern vaccinology. New York: Plenum Medical Book Company; 1994. p. 55-86.
20. Hormaeche CE, Khan CMA, Mastroeni P, et al. Salmonella vaccines: mechanisms of immunity and their use as carriers of recombinant antigens. In: Ala'Aldeen D, Hormaeche CE, editors. Molecular and clinical aspects of bacterial vaccine development. London: Wiley; 1995. p. 119-53.
21. Hone DM, Shata MT, Pascual DW, Lewis GK. Mucosal vaccination with Salmonella vaccine vectors. In: Patterson Y, editor. Intracellular bacterial vaccine vectors: immunology, cell biology and genetics. London: Wiley; 1999. p. 171-222.
22. Leary S.E.C., Griffin K.F., Garmory H.S., Williamson E.D., Titball R.W. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb. Pathog. 23:1997;167-179.
23. Sambrook J, Frtisch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed. New York: Cold Spring Harbour Laboratory Press, 1989.
24. Lawton D.G., Longstaff C., Wallace B.M.et al. Interactions of the type III secretion pathway proteins LcrV and LcrG from Yersinia pestis are mediated by coiled-coil domains. J. Biol. Chem. 277:2002;38714-38722.
25. Amann E., Ochs B., Abel K.J. Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli. Gene. 69:1988;301-315.
26. Russell P., Eley S.M., Hibbs S.E., Manchee R.J., Stagg A.J., Titball R.W. A comparison of plague vaccine USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine. 13:1995;1551-1556.
27. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin. Exp. Immunol. 116:1999;107-114.
28. Hill J., Leary S.E.C., Griffin K.F., Williamson E.D., Titball R.W. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect. Immun. 65:1997;4476-4482.
29. Hill J, Leary SEC, Titball RW. An in vitro correlate of antibody mediated protection against bubonic plague. In: Proceedings of the 100th General Meeting of the American Society of Microbiology, Los Angeles, 2000, Abstract E-2. p. 293.
30. Garmory H.S., Griffin K.F., Leary S.E.C., Perkins S.D., Brown K.A., Titball R.W. The effect of recombinant plasmids on in vivo colonisation of Salmonella enterica serovar Typhimurium strains is not reflected by in vitro cellular invasion assays. Vaccine. 20:2002;3239-3243.
31. Mittrûcker H.-W., Kaufmann S.H.E. Immune response to infection with Salmonella typhimurium in mice. J. Leukocyte Biol. 67:2000;457-463.
32. Titball R.W., Howells A.M., Oyston P.C.F., Williamson E.D. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect. Immun. 65:1997;1926-1930.
33. Winter C.C., Cherry W.B., Moody M.D. An unusual strain of Pasteurella pestis isolated from a fatal human case of plague. Bull. WHO. 23:1960;408-409.